Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Intracranial Hypotension
Interventions: MRI algorithm, Lumbar puncture, Epidural patching; Device · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3, Midazolam, Repaglinide, Digoxin, Rosuvastatin; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Intubation Complication
Interventions: Etomidate, Ketamine; Drug
Lead sponsor: South East Area Health Education Center, Wilmington, NC; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Type 1 Diabetes
Interventions: Extended Wear infusion set, Standard Infusion set, Heparin; Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Visual Acuity
Interventions: TRP-200, JJVC Marketed Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 12
States / cities: Jacksonville, Florida • Orange Park, Florida • Tallahassee, Florida + 9 more

Conditions: Clinical Pharmacology, Pharmacokinetics, Cardiovascular Diseases, Heart Failure
Interventions: CRD-740, Itraconazole; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Interventions: Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 22
States / cities: Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more

Conditions: Healthy Male Participants
Interventions: Vimseltinib, Dabigatran; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psychophysiological Reactivity and Recovery
Interventions: Brief Standardized Mindfulness/Attention Instruction; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Omaha, Nebraska

Conditions: Obsessive-Compulsive Disorder
Interventions: Activa PC+S DBS implant for OCD, One Month Blinded Discontinuation Period; Device · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas

Conditions: Obesity
Interventions: Danuglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Anaheim, California • South Miami, Florida

Conditions: Laryngeal Dystonia, Spasmodic Dysphonia, Tremor
Interventions: Brain imaging, Laryngeal sensory block with topical bupivacaine; Other · Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 80 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: VRG50635, Placebo; Drug
Lead sponsor: Verge Genomics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Intellectual Disabilities (F70-F79), Autism
Interventions: Operant Conditioning Tasks with Reinforcement Manipulations; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Auburn, Alabama • Baltimore, Maryland • Rochester Hills, Michigan

Conditions: Healthy
Interventions: Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solitary Pulmonary Nodule, Multiple Pulmonary Nodules, Lung Neoplasms, Lung Cancer Screening
Interventions: Multiparametric chest MRI with diffusion-weighted imaging; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Stage A Adult Primary Liver Cancer (BCLC), Stage B Adult Primary Liver Cancer (BCLC)
Interventions: 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent); Device · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mild Cognitive Impairment
Interventions: Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules, Treatment As Usual; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Participants
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: CEP-701, high-dose cytarabine, Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy); Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 34
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Refractive Error Correction
Interventions: Test/Control, Control/Test; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pancreatic Cancer, Thymic Cancer, Parathyroid Disease, MEN1 Syndrome
Interventions: Blood draw; Genetic
Lead sponsor: Jersey Shore University Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Glioma, Glioma of Brain, Glioma of Spinal Cord
Interventions: Multilingual Aphasia Examination, Language paradigms + RS fMRI, Language paradigms + RS fMRI + one anatomical sequence; Behavioral · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

Evaluation of Prototype Lenses With Experimental UV/HEV Blocker

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants

Physiology of Liberation

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Development of Adaptive Deep Brain Stimulation for OCD (Phase 1a)

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor

A Study of VRG50635 in Healthy Volunteers

Optimizing Dimensions of Reinforcement

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Assessing and Improving the Durability of Compensatory Cognitive Training for Older Veterans

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process

Genetic Evaluation of Families With Endocrine Cancers

Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently